A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).
Status:
Completed
Trial end date:
2021-01-22
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that early institution of TNFα inhibitor therapy in patients
with severe COVID-19 infections will prevent further clinical deterioration and reduce the
need for advanced cardiorespiratory support and early mortality. To address this hypothesis,
a prospective, single center, phase 2 trial is proposed to assess the efficacy of infliximab
or infliximab-abda in hospitalized adult patients with severe or critical COVID-19.
Observations from this study will inform the conduct of prospective randomized controlled
studies to follow.